Back to top

Image: Bigstock

The Medicines Company

Read MoreHide Full Article

The Medicines Co.’s third-quarter results were mixed with the company posting a narrower-than-expected loss and revenues missing expectations marginally. With Angiomax facing generic competition, sales have dropped significantly. However, with the company’s request for a rehearing of its appeal for Angiomax being granted, a favorable decision would be a major positive. Meanwhile, the company’s increasing focus on the launch of recently approved products and restructuring initiatives to boost shareholder value are encouraging. Investor focus will remain on the performance of newly launched products, the company’s progress on its restructuring plans and the Angiomax rehearing.